Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 6, 2002, Pages 464-472

  Assan, Roger ^a   Blanchet, Françoise ^a   Feutren, Gilles ^b   Timsit, José ^c   Larger, Etienne ^a,c   Boitard, Christian ^c   Amiel, Claude ^a   Bach, Jean François ^c  

^a BICHAT HOSPITAL   (France)

^b Novartis Institute for BioMedical Research Basel   (Switzerland)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cyclosporin; Diabetes; Hypertension; Immunotherapy; Kidney; Nephrotoxicity

Indexed keywords

4 AMINOHIPPURIC ACID; AMINO ACID; ANTIHYPERTENSIVE AGENT; CREATININE; CYCLOSPORIN A; ENALAPRIL; INSULIN; INSULIN ZINC SUSPENSION; INULIN; ISOPHANE INSULIN; NEUTRAL INSULIN; PLACEBO;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INULIN CLEARANCE; KIDNEY BIOPSY; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NEPHROTOXICITY; PARALLEL DESIGN; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RETINOPATHY; TIME;

ADULT; AUTOIMMUNE DISEASES; CREATININE; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INULIN; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; PREGNANCY; PROTEINURIA; TIME FACTORS; VASCULAR RESISTANCE;

EID: 0036868812     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.325     Document Type: Article

References (53)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
2. Assan R, Feutren G, Debray-Sachs M, et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1985; 1: 67-71.
3. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2: 119-124.
4. The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574-1582.
5. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663-670.
6. Fathman CG, Myers BD. Cyclosporine therapy for autoimmune disease. N Engl J Med 1992; 326: 1693-1695.
7. Mihatsch MJ, Thiel G, Ryffel B. Morphology of cyclosporin nephropathy. Prog Allergy 1986; 38: 447-465.
8. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. (International kidney biopsy registry of cyclosporine in autoimmune diseases). N Engl J Med 1992; 326: 1654-1660.
9. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
10. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590-600.
11. Palestine AG, Austin HA 3D, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293-1298.
12. Austin HA 3d, Palestine AG, Sabnis SG, et al. Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis. Am J Nephrol 1989; 9: 392-402.
13. Lewis RM, Janney RP, Golden DL, et al. Stability of renal allograft function associated with long-term cyclosporine immunosuppressive therapy-five year follow-up. Transplantation 1989; 47: 266-272.
14. Salomon DR. Cyclosporine nephrotoxicity and long-term renal transplantation. Transplant Rev 1992; 6: 10-19.
15. Yocum DE. Cyclosporine in rheumatoid arthritis: beyond experimentation. Semin Arthritis Rheum 1992; 21: 39-42.
16. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
17. Silverman AK, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function? Semin Dermatol 1992; 11: 302-312.
18. De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346.
19. Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol 1999; 28: 65-68.
20. Andoh TF, Bennett WM. Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 1998; 7: 265-270.
21. Parving HH, Tarnow L, Nielsen FS, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999; 22: 478-483.
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
23. Assan R, Feutren G, Sirmai J, et al. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Diabetes 1990; 39: 768-774.
24. Macias-Nunez JF, Cameron JS. Renal function in the elderly. In Oxford Textbook of Clinical Nephrology, Cameron S, Davison AM, Grunfeld JP, Kerr D, Ritz E (eds). Oxford University Press: Oxford, 1992; 56-69.
25. Friedlander G, Blanchet-Benque F, Nitenberg A, Laborie C, Assan R, Amiel C. Glucagon secretion is essential for aminoacid-induced hyperfiltration in man. Nephrol Dial Transplant 1990; 5: 110-117.
26. Assan R, Timsit J, Feutren G, et al. The kidney in cyclosporin A-treated diabetic patients: a long-term clinicopathological study. Clin Nephrol 1994; 41: 41-49.
27. Mogensen CE. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 1986; 46: 201-206.
28. Editorial (anonymous). Cyclosporin for ever? Lancet 1986; 1: 419, 420.
29. Zietse R, Balk AH, Van Der Dorpel MA, Meeter K, Bos E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14: 1-5.
30. Burke Jr JF, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994; 331: 358-363.
31. Williams AW, Morgenstern BZ, Murphy M, Milliner DS. Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. Pediatr Nephrol 1994; 8: 566-569.
32. Lewis RM. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int Suppl 1995; 52: S75-S78.
33. Sund S, Forre O, Berg KJ, Kvien TK, Hovig T. Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol 1994; 41: 33-40.
34. Svarstad E, Helland S, Morken T, et al. Renal effects of maintenance low-dose cyclosporin A treatment in psoriasis. Nephrol Dial Transplant 1994; 9: 1462-1467.
35. Klompmaker IJ, Homan Van Der Heide JJ, Tegzess AM, et al. Effects of cyclosporin A withdrawal on renal function and renal stimulation in liver transplant patients treated with triple-drug immunosuppression for over 2 years. Nephrol Dial Transplant 1994; 9: 1629-1633.
36. Zachariae H, Hansen HE, Kragballe K, Olsen S. Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens. J Am Acad Dermatol 1992; 26: 415-419.
37. Lafayette RA, Mayer G, Meyer TW. The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 1993; 3: 1892-1899.
38. Powles AV, Hardman CM, Porter WM, Cook T, Hulme B, Fry L. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443-449.
39. Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39: 1264-1272.
40. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983.
41. Bobadilla NA, Tapia E, Franco M, et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 1994; 46: 773-779.
42. Gaston RS, Schlessinger SD, Sanders PW, Barker CV, Curtis JJ, Warnock DG. Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients. J Am Soc Nephrol 1995; 5: 1426-1433.
43. Hunley TE, Fogo A, Iwasaki S, Kon V. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 1995; 5: 1718-1723.
44. Torras J, Valles J, Sanchez J, et al. Prevention of experimental cyclosporine nephrotoxicity by dietary supplementation with LSL 90202, a lysine salt of eicosapentaenoic acid. Role of thromboxane and prostacyclin in renal tissue. Nephron 1994; 67: 66-72.
45. Starklint H, Hansen HV, Kemp M, Leyssac PP, Kemp E, Dieperink H. Long-term cyclosporin A nephrotoxicity in the rat. Evaluation of a morphological scoring system and of co-treatment with isradipine. APMIS 1994; 102: 347-355.
46. White Jr JR, Rockwood T, Wilson D, Bettesworth L, Icenogle T. The effects of pentoxifylline on the prevention of cyclosporine-induced nephrotoxicity in cardiac transplant patients. Clin Ther 1994; 16: 673-679.
47. Massicot F, Warnet JM, Dutertre-Catella H, Martin C, Braquet P, Claude JR. Protection against cyclosporin-induced nephrotoxicity: 1. Effect of a PAF antagonist, BN50726. J Lipid Mediat Cell Signal 1994; 9: 217-224.
48. Markewitz A, Hammer C, Pfeiffer M, et al. Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation. Transplantation 1994; 57: 865-870.
49. Xu F, Huang JB, Jiang L, Xu J, Mi J. Amelioration of cyclosporin nephrotoxicity by Cordyceps sinensis in kidney-transplanted recipients. Nephrol Dial Transplant 1995; 10: 142, 143.
50. Grieve EM, Hawksworth GM, Simpson JG, Whiting PH. The reversal of experimental cyclosporin A nephrotoxicity by thromboxane synthetase inhibition. Biochem Pharmacol 1993; 45: 1351-1354.
51. Smith SR, Kubacki VB, Rakhit A, et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation 1993; 56: 1422-1426.
52. Perico N, Rossini M, Imberti O, et al. Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. J Am Soc Nephrol 1992; 2: 1398-1404.
53. Smith SR, Creech EA, Schaffer AV, et al. Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Kidney Int 1992; 41: 199-205.